Tag Archives: Imprimis

Imprimis Pharmaceuticals: Application published: “Epinephrine-Based Ophthalmic Compositions for Intraocular Administration and Methods for Fabricating Thereof”

March 1, 2018: The USPTO today published a patent application filed by Imprimis Pharmaceuticals of San Diego, CA: U.S. Application Publication No. 2018/0055790, “Epinephrine-Based Ophthalmic Compositions for Intraocular Administration and Methods for Fabricating Thereof”.

According to the published abstract:

Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described.

Published Claim 1 recites:

1. A method for preparing a pharmaceutical composition, the method comprising:
(a) preparing an aqueous composition consisting of:
(a1) a therapeutically effective quantity of at least one compound selected from the group consisting of epinephrine, phenylephrine, EPI-Shugarcaine and tropicamide;
(a2) at least one metal chelator;
(a3) optionally, at least one anesthetic;
(a4) optionally, at least one non-steroid anti-inflammatory drug; and
(a5) a quantity of sterile water, wherein the composition is optionally free of sulfites and is free of preservatives; and
(b) lyophilizing the aqueous composition, to obtain thereby the lyophilized pharmaceutical composition.

The published application can be viewed at the USPTO website at http://pdfaiw.uspto.gov/.aiw?Docid=20180055790.

Note: A published application is not an issued patent. The USPTO automatically publishes most applications 18 months after filing, and the publication is simply a copy of the as-filed application, without examination.

Imprimis Pharmaceuticals Sells Pennsylvania Facility and Sinus Assets

In a move said to focus resources on its rapidly-growing core ophthalmology business, Imprimis Pharmaceuticals, Inc. of San Diego, CA, announced on June 29, 2017 that it has entered into an agreement to sell its Folcroft, Pennsylvania facility and sinus related assets for $450,000.

According to the announcement, the closing of this transaction is expected to occur on or around July 17, 2017, subject to customary terms and conditions.
Continue reading

Imprimis announces Peer-Reviewed Paper on the Benefits of Dropless Cataract Surgery®

Imprimis Pharmaceuticals, Inc. of San Diego, CA, announced on March 20, 2017 the publication of a Dropless Therapy® article in the peer-reviewed journal, Current Pharmaceutical Design. Dropless Cataract Surgery® is a single-use, injectable combination of antibiotic and steroid formulation administered at the end of cataract surgery to essentially eliminate the need for post-surgery eye drops. The authors provide a retrospective review of data and efficacy of the Dropless® approach, examine the transzonular via cannula injection technique, and discuss the benefits of Dropless Therapy® to patients, physicians and their staff. Continue reading

Imprimis: Application published: “Epinephrine-Based Ophthalmic Compositions for Intraocular Administration and Methods for Fabricating Thereof”

February 23, 2017: The USPTO today published a patent application filed by Imprimis Pharmaceuticals, Inc. of San Diego, CA: U.S. Application Publication No. 2017/0049721, “Epinephrine-Based Ophthalmic Compositions for Intraocular Administration and Methods for Fabricating Thereof”.

According to the published abstract:

Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described.

The published application can be viewed at the USPTO website at http://pdfaiw.uspto.gov/.aiw?Docid=20170049721.

Note: A published application is not an issued patent. The USPTO automatically publishes most applications 18 months after filing, and the publication is a simply copy of the as-filed application, without examination.

Imprimis Pharmaceuticals Announces $9.8 Million Private Placement

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) on December 19, 2016, announced that it has entered into a definitive securities purchase agreement with various accredited investors and certain members of Imprimis’ Board of Directors and senior management, including the CEO, CFO, and Senior Director of Corporate Development, to raise gross proceeds of approximately $9.8 million in a private placement of Units.

Continue reading

Imprimis: Application published: “Epinephrine-Based Ophthalmic Compositions For Intraocular Administration And Methods For Fabricating Thereof”

December 8, 2016: The USPTO today published a patent application filed by Imprimis Pharmaceuticals, Inc. of San Diego, CA : U.S. Application Publication No. 2016/0354308, “Epinephrine-Based Ophthalmic Compositions For Intraocular Administration And Methods For Fabricating Thereof”.

According to the published abstract:

Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described.

The published application can be viewed at the USPTO website at http://pdfaiw.uspto.gov/.aiw?Docid=20160354308.

Note: A published application is not an issued patent. The USPTO automatically publishes most applications 18 months after filing, and the publication is a copy of the as-filed application, without examination.